InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Banjo50 Free
07/06/23 7:28 PM
Post #4,987
profile icon
MASTERULTRA Free
05/24/23 10:48 AM
Post #4,986
profile icon
Awl416 Free
05/24/23 7:41 AM
Post #4,985
profile icon
Awl416 Free
05/16/23 7:48 AM
Post #4,984
profile icon
Awl416 Free
04/18/23 12:29 PM
Post #4,983
profile icon
BEIJING BILL Free
04/18/23 12:17 PM
Post #4,982
profile icon
TheFinalCD PremiumMember
04/18/23 10:58 AM
Post #4,980
profile icon
BEIJING BILL Free
04/18/23 10:50 AM
Post #4,979
Bullish
Bullish
profile icon
TheFinalCD PremiumMember
04/18/23 10:16 AM
Post #4,978
profile icon
tw0122 Free
02/10/23 9:10 AM
Post #4,975
profile icon
spindog Free
01/06/23 1:42 PM
Post #4,974
profile icon
makinezmoney Free
01/06/23 1:37 PM
Post #4,973
profile icon
makinezmoney Free
01/06/23 1:31 PM
Post #4,972
profile icon
trendzone Free
10/25/22 2:29 PM
Post #4,971
profile icon
trendzone Free
10/19/22 3:49 PM
Post #4,970
profile icon
the submariner Free
10/19/22 12:11 PM
Post #4,969
profile icon
trendzone Free
10/13/22 11:12 AM
Post #4,968
profile icon
the submariner Free
05/18/22 4:32 PM
Post #4,967
profile icon
trendzone Free
05/18/22 12:24 PM
Post #4,966
profile icon
trendzone Free
05/16/22 8:34 AM
Post #4,964
profile icon
trendzone Free
04/26/22 10:51 AM
Post #4,963
profile icon
sick nam vet Free
04/18/22 3:52 PM
Post #4,962
profile icon
sick nam vet Free
04/18/22 2:25 PM
Post #4,961
profile icon
sick nam vet Free
04/18/22 2:24 PM
Post #4,960
profile icon
sick nam vet Free
04/17/22 9:48 PM
Post #4,959
profile icon
trendzone Free
04/16/22 12:16 PM
Post #4,958
profile icon
trendzone Free
04/16/22 12:11 PM
Post #4,957
profile icon
sick nam vet Free
04/14/22 10:56 PM
Post #4,956
profile icon
trendzone Free
04/14/22 5:24 PM
Post #4,955
profile icon
sick nam vet Free
04/14/22 2:55 PM
Post #4,954
profile icon
trendzone Free
04/13/22 5:18 PM
Post #4,953
profile icon
sick nam vet Free
04/13/22 10:45 AM
Post #4,952
profile icon
trendzone Free
04/11/22 11:48 PM
Post #4,951
profile icon
Laloo77 Free
04/11/22 2:32 PM
Post #4,950
profile icon
trendzone Free
04/11/22 12:10 PM
Post #4,949
profile icon
BeasTrader Free
04/11/22 10:44 AM
Post #4,948
profile icon
MASTERULTRA Free
04/11/22 7:35 AM
Post #4,947
profile icon
knrorrel Free
04/11/22 12:41 AM
Post #4,946
profile icon
knrorrel Free
04/11/22 12:29 AM
Post #4,944
profile icon
logsplitter Free
04/10/22 5:10 PM
Post #4,943
profile icon
knrorrel Free
04/10/22 2:44 AM
Post #4,942
profile icon
Harbor6460 Free
04/09/22 12:00 PM
Post #4,940
profile icon
02opida PremiumMember
04/09/22 8:51 AM
Post #4,939
profile icon
PStockPickz Free
04/08/22 5:04 PM
Post #4,938
profile icon
TheFinalCD PremiumMember
04/08/22 4:52 PM
Post #4,937

Phio Pharmaceuticals Corp (PHIO)

Followers
135
Posters
374
Posts (Today)
0
Posts (Total)
4987
Created
05/10/12
Type
Free
Moderators

About Phio Pharmaceuticals Corp. (PHIO)

Shares Outstanding 13.53M
Float  13.48M
 

Phio is addressing some of the biggest challenges in immuno-oncology (I/O) by developing therapeutics that leverage our INTASYL™ self-delivering technology to target both tumor and immune cells. The I/O field has recently identified several promising next-generation targets, but conventional approaches such as antibodies and small molecules often fall short of becoming optimal treatments for patients. In contrast to conventional RNA inference (RNAi) platforms, our INTASYL™ enables efficient RNAi delivery into any cell of interest. INTASYL™ therefore brings the benefits of RNAi therapeutics into the I/O space to develop new and potent next-generation I/O therapeutics with favorable drug profiles for patients with cancer.

PH-762

Our lead product, PH-762, activates immune cells to better recognize and kill cancer cells. It does so by reducing the expression of PD-1, a clinically validated target for immunotherapy. PD-1 is expressed by T-cells and helps keep them from killing other cells, including cancer cells. Reducing PD-1 expression can reduce the ability of cancer cells to avoid T-cell detection. Like any other INTASYL™ self-delivering RNAi therapeutic, it can be used either via local administration to a tumor (to modify the tumor microenvironment); or to improve immune cells for ACT.

PIPELINE



   
Most Liked Posts
(Last 30 Days)
New Post